Exagen Stock Price Fell 8.70% on a $650K DoJ Kickbacks Settlement

The Exagen Inc (NASDAQ: XGN) stock price fell 8.70% after the company agreed to pay $650,143 to resolve allegations regarding payments made to referring physicians. The company is accused of providing specimen processing fees to motivate physicians to use its laboratory tests, a practice deemed unethical and potentially illegal.

As part of the settlement, Exagen has admitted to making payments to specific referring physicians for conducting blood draws from patients in connection with specimen processing agreements. These agreements were established between Exagen and the physicians, further implicating the company in alleged wrongdoing.

The Department of Justice (DOJ) notes that Exagen went on to bill federal healthcare programs, which include Medicare, for the diagnostic tests it conducted after receiving orders from these physicians. 

The practice continued even after the company became aware of a fraud alert issued by the Department of Health & Human Services' Office of the Inspector General in June. 

The settlement reached with the DOJ results from allegations initially brought to light by a whistleblower. This whistleblower will receive a portion of the recovered settlement, equivalent to 16% of the total amount.

This case underscores the importance of transparency, compliance, and ethical business practices in the healthcare industry. Incentivising physicians to refer patients for laboratory tests can compromise the integrity of healthcare decisions and may result in fraudulent billing practices. 

Exagen's agreement to settle and admit to certain practices is a reminder of the consequences that can follow when healthcare companies engage in activities that undermine the principles of fair and ethical healthcare provision.

In the face of these allegations, Exagen, like many healthcare entities, is presented with an opportunity to review and strengthen its compliance policies, ensuring that its future operations align with ethical standards and legal requirements.

Furthermore, this case highlights the vital role played by whistleblowers in holding companies accountable for their actions in the healthcare sector, ultimately safeguarding the interests of patients and the integrity of the healthcare system.

Exagen stock price. 

The Exagen (XGN) stock price was trading up 22.02% at $2.05 after hours following yesterday’s 8.70% decline.